FSL-1 TFA|西域试剂

FSL-1 TFA,99.30%

产品编号：Bellancom-P2036A| 分子式：C₈₂H₁₄₁F₃N₁₄O₂₀S| 分子量：1780.18

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P2036A		￥1600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FSL-1 TFA

产品介绍

FSL-1 TFA 是细菌衍生的一种 Toll 样受体 2/6 (TLR2/6) 激动剂，可增强对 HSV-2 感染的抵抗力。FSL-1 TFA 通过 TLR2 和 NF-κB/AP-1 信号通路诱导 MMP-9 产生。

生物活性

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells.

体外研究

FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC).
FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile.
FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells.
FSL-1 activates the MAP kinase/NF-κB signaling pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	V11I, V12I or V19I immortalized human vaginal EC
Concentration:	6 μg or 0.1 μg
Incubation Time:	Added at 24, 6 or just prior to HSV-2 inoculation (10⁴pfu/well)
Result:	The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.

体内研究
(In Vivo)

FSL-1 application significantly protectes against genital HSV-2 challenge in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Swiss-Webster mice (weighing 20-25 g)
Dosage:	2 or 6 μg
Administration:	Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment.
Result:	The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control. The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application.

体内研究

FSL-1 application significantly protectes against genital HSV-2 challenge in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Swiss-Webster mice (weighing 20-25 g)
Dosage:	2 or 6 μg
Administration:	Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment.
Result:	The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control. The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application.

体内研究

FSL-1 application significantly protectes against genital HSV-2 challenge in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Swiss-Webster mice (weighing 20-25 g)
Dosage:	2 or 6 μg
Administration:	Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment.
Result:	The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control. The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application.